ClinicalTrials.gg
Not yet recruitingNCT07847697Updated Nov 10, 2026

A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, PK/PD Characteristics, and Efficacy of SCTB10

A Phase 1 interventional study of SCTB10 and Placebo in Healthy Participants, sponsored by Sinocelltech Ltd.. Not yet recruiting at 1 site in China. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Sinocelltech Ltd. (part of Sinocelltech Group Limited) · Phase 1, Interventional, and Treatment

Updated Nov 10, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

Phase Ia to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of SCTB10 following a single dose in healthy participants

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Sinocelltech Ltd. is the lead sponsor of 82 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of written prior to initiation of any study procedures.
  2. Healthy male participants aged 18 to 50 years (inclusive).
  3. (BMI) between 19 and 26 kg/m² (inclusive), and body weight ≥ 50 kg.
  4. Agreement by the participant and their partner to use highly effective during the study period and for 6 months following the last dose of study medication.

Exclusion criteria

Exclusion Criteria:

  1. History of or allergy to monoclonal antibodies, or a known atopic constitution.
  2. History of coronary and/or peripheral atherosclerosis, or congestive heart failure.
  3. Presence of high-risk factors for thrombosis.
  4. abnormal findings during screening, as determined by the investigator.
  5. Abnormal infectious disease screening results.
  6. Abnormal results in urine drug screening or breath alcohol test.
  7. Use of any medication or dietary supplements within 14 days prior to the first dose.
  8. Participation in another clinical trial involving the use of any drug or medical device within 12 weeks prior to screening.
  9. Receipt of any biologic products (including antibodies or their derivatives) within 16 weeks prior to dosing (or within 5 half-lives, whichever is longer).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
12 participants (estimated)

Study arms

  • Placebo comparator
    Placebo group

    Drug: Placebo

  • Experimental
    SCTB10 group

    Drug: SCTB10

Interventions

  • DrugSCTB10

    SCTB10 will be subcutaneously administered as a single dose in healthy volunteers

  • DrugPlacebo

    Placebo will be subcutaneously administered in Healthy Volunteers

06

What researchers measure

Primary outcomes

  1. dose limited toxicity (DLT).

    To determine the maximum tolerated dose (MTD) and/or RP2D.

    Time frame: Up to approximately 6 weeks.

  2. Incidence of TEAE.

    TEAE refers to 'treatment emergent adverse event'.

    Time frame: Up to approximately 25 weeks.

  3. Incidence of TRAE.

    Incidence of TEAE related to the experimental drug.

    Time frame: Up to approximately 25 weeks.

  4. Incidence of SAE.

    SAE refers to 'serious adverse event'.

    Time frame: Up to approximately 25 weeks

Secondary outcomes

  1. Blood Concentrations of SCTB10

    The pharmacokinetics of SCTB10 will be analyzed based on the drug concentrations at respective timepoints in the blood samples (or blood derivative)

    Time frame: Up to approximately 25 weeks

  2. Activated Partial Thromboplastin Time and Thrombin Generation Assay

    pharmacodynamics

    Time frame: Up to approximately 25 weeks

  3. Incidence of anti-SCTB10 antibody (ADA) and neutralizing antibody (Nab).

    immunogenicity

    Time frame: Up to approximately 25 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Jun 2029, 31 months later.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2026
First posted
Sep 29, 2026
StartEst.
Nov 30, 2026was Sep 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Aug 30, 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 30, 2026→Nov 30, 2026
Nov 10, 2026
Registered
First appeared on the registry
Sep 29, 2026
Show all 2 updates
  1. Nov 10, 2026
    Start date Sep 30, 2026→Nov 30, 2026
    + 1 other change: verification date
  2. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07847697
Lead sponsor
Sinocelltech Ltd.
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Jun 30, 2029 (estimated)
Completion
Aug 30, 2029 (estimated)
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion